| Athrectomy and Drug Eluting Balloon Therapy (ADEBT) on the Femoral Popliteal Arteries (NCT02686541) | Changi General Hospital | 2015-04-01 |
| Efficacy of an Intradialysis Combined Training Program on Disability Level and Physical Performance. (NCT02883309) | Universidad Austral de Chile | 2013-11-01 |
| Influence of Preoperative Enema Application on Return of Gastrointestinal Function After Elective Cesarean Section: A Randomized Controlled Study (NCT01917396) | Istanbul Bakirkoy Maternity and Children Diseases Hospital | 2013-08-01 |
| Afatinib Expanded Access Program (NCT01649284) | Boehringer Ingelheim | 2012-07-01 |
| An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory (NCT01240421) | Eisai Inc. | 2011-03-01 |
| A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma (NCT01160250) | Genentech, Inc. | 2010-07-01 |
| SynCardia Freedom Driver System Study (NCT00733447) | SynCardia Systems. LLC | 2010-03-01 |
| Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects (NCT00918424) | Supernus Pharmaceuticals, Inc. | 2009-06-01 |
| Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase (NCT00905593) | Novartis Pharmaceuticals | 2008-09-01 |
| Comparison of Biodegradable and Titanium Fixation Systems in Mandibular Symphysis or Parasymphysis Solitary Fractures (NCT02181868) | Louqiang Zhang | 2008-01-01 |
| EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer (NCT00338247) | Novartis | 2006-07-01 |
| Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease (NCT00293098) | Children's Hospital of Philadelphia | 2006-03-01 |
| Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection (NCT00338442) | Cangene Corporation | 2006-02-01 |
| Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection (NCT00097799) | Boehringer Ingelheim | 2004-12-01 |
| Long Term Treatment With L-DOPS (NCT00889135) | Vanderbilt University | 2004-09-01 |
| A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248 (NCT00094029) | Pfizer | 2004-09-01 |
| Post Approval Continued Access Study of the MENTOR® Contour Profile Gel Breast Implant (NCT00811525) | Mentor Worldwide, LLC | 2004-08-01 |
| An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options. (NCT00933205) | Boehringer Ingelheim | 2004-05-01 |
| Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease (NCT00074919) | Genzyme, a Sanofi Company | 2003-12-01 |
| Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization (NCT00291811) | Genzyme, a Sanofi Company | 2003-10-01 |
| An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis (NCT05344508) | Insmed Incorporated | |
| VX-770 Expanded Access Program (NCT01381289) | Vertex Pharmaceuticals Incorporated | |
| Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children (NCT02328768) | University of Nebraska | |
| Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy (NCT02660255) | University of Nebraska | |
| Zenith® Dissection Endovascular System in the Treatment of Patients With Aortic Dissections (NCT02464943) | Cook Research Incorporated | |
| Multicenter Single-port Colectomy RCT (NCT01480128) | The Catholic University of Korea | |
| Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP) (NCT02171156) | Boehringer Ingelheim | |
| Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection (NCT00499720) | Gilead Sciences | |
| TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma (NCT00906984) | University of California, Irvine | |
| Compassionate Use of Pennsaid Topical Lotion (Diclofenac) in Osteo or Rheumatoid Arthritis (NCT01579890) | Mallinckrodt | |
| Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD) (NCT05544032) | Incyte Corporation | |
| An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck (NCT00684385) | AstraZeneca | |
| Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer (NCT02792725) | Eli Lilly and Company | |
| Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD (NCT05722912) | Incyte Corporation | |
| 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS) (NCT00872950) | Lahey Clinic | |
| Compassionate Use of Pozelimab (NCT05232110) | Regeneron Pharmaceuticals | |
| Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease (NCT03072667) | Catherine Cibulskis, MD | |
| Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone (NCT02141087) | Genentech, Inc. | |
| Compassionate Use Program for Olipudase Alfa Enzyme Replacement Therapy for Patients With Chronic Acid Sphingomyelinase Deficiency (ASMD) (NCT04877132) | Sanofi | |
| Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab (NCT00650390) | Abbott | |
| Expanded Access Protocol of 68Ga-PSMA-11 for PET Imaging (NCT04348682) | Jonsson Comprehensive Cancer Center | |
| Clinical Evaluation of Cardiac Resynchronization Therapy (CRT) Using the Ovatio CRT Implantable Cardioverter-defibrillator (ICD) System (NCT00528320) | ELA Medical, Inc. | |
| Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease (NCT01297933) | Children's Hospital of Philadelphia | |
| Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI) (NCT02437500) | Seres Therapeutics, Inc. | |
| Expanded Access for Treatment With Imetelstat (NCT05937568) | Geron Corporation | |
| Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat (NCT06628713) | KalVista Pharmaceuticals, Ltd. | |
| Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma (NCT02961491) | Molecular Insight Pharmaceuticals, Inc. | |
| HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC (NCT02436044) | Ming Zhao | |
| Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer. (NCT03079687) | AstraZeneca | |
| Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer (NCT04599712) | Janssen Research & Development, LLC | |
| Expanded Access for Bulevirtide (NCT06780579) | Gilead Sciences | |
| A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease (NCT02963350) | BioMarin Pharmaceutical | |
| Expanded Access for Hereditary Angioedema (HAE) (NCT03177005) | Joshua S. Jacobs, MD | |
| Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR) (NCT02939820) | Alnylam Pharmaceuticals | |
| Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination) (NCT05401214) | Janssen Research & Development, LLC | |
| Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections (NCT03780140) | Shionogi | |
| Cenobamate Expanded Access Program (EAP) (NCT04513860) | SK Life Science, Inc. | |
| Use of Avanta Metacarpophalangeal (MCP) Joint Implant Finger Prosthesis, Humanitarian Use Device (NCT02244775) | Hospital for Special Surgery, New York | |
| Effect of Cryostimulation on Selected Motor Skills in Soccer Players (NCT06812819) | Poznan University of Physical Education | |
| Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer (NCT02286492) | Taiho Oncology, Inc. | |
| A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS) (NCT04530994) | Mirum Pharmaceuticals, Inc. | |
| Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer (NCT03763604) | Eli Lilly and Company | |
| Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas (NCT04617002) | Jazz Pharmaceuticals | |
| Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD (NCT02929303) | Wake Forest University Health Sciences | |
| Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab (NCT04247906) | Omeros Corporation | |
| Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients (NCT05463939) | Janssen Research & Development, LLC | |
| Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis (NCT01464762) | Janssen Infectious Diseases BVBA | |
| Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) (NCT03070093) | Astellas Pharma Global Development, Inc. | |
| Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer (NCT01217697) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly (NCT01995734) | Novartis Pharmaceuticals | |
| An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (NCT01833039) | Janssen Biotech, Inc. | |
| Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (NCT04507503) | Taiho Oncology, Inc. | |
| Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome (NCT01825395) | University of Colorado, Denver | |
| Emergency/Compassionate Use PFO Occluder (NCT00584064) | Abbott Medical Devices | |
| Oral Berotralstat Expanded Access Program (NCT04428632) | BioCryst Pharmaceuticals | |
| Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma (NCT04534322) | Oncopeptides AB | |
| Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer (NCT06064500) | Amgen | |
| ATTR Expanded Access Program (EAP) by Ionis (NCT03400098) | Ionis Pharmaceuticals, Inc. | |
| An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia (NCT03501615) | AstraZeneca | |
| Expanded Access Use of Cemiplimab in Patients With Solid Tumors (NCT06132191) | Regeneron Pharmaceuticals | |
| Alglucosidase Alfa Temporary Access Program (NCT00520143) | Genzyme, a Sanofi Company | |
| An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations (NCT04535557) | Millennium Pharmaceuticals, Inc. | |
| Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of the Thoracoabdominal and Pararenal Aortic Aneurysms (TAMBE) (NCT05442489) | W.L.Gore & Associates | |
| Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN. (NCT02969174) | Shanghai Tongji Hospital, Tongji University School of Medicine | |
| Pre-Approval Access to Rilpivirine Long Acting (RPV LA) Injectable Suspension for the Treatment of a Participant With Human Immunodeficiency Virus (HIV)-1 Infection (NCT03847376) | Janssen Sciences Ireland UC | |
| Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 (NCT04338360) | Mayo Clinic | |
| BMN 110 US Expanded Access Program (NCT01858103) | BioMarin Pharmaceutical | |
| Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil (NCT03533361) | Eisai Inc. | |
| Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis (NCT00649545) | Abbott | |
| Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B (NCT01198860) | Nguyen Thi Trieu, MD | |
| Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression (NCT03924492) | Supernus Pharmaceuticals, Inc. | |
| Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma (NCT05760586) | Day One Biopharmaceuticals, Inc. | |
| Expanded Access Protocol to Provide Lumasiran to Patients With Primary Hyperoxaluria Type 1 (NCT04125472) | Alnylam Pharmaceuticals | |
| C3G/Primary IC-MPGN EAP (NCT04729062) | Apellis Pharmaceuticals, Inc. | |
| A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA (NCT04291937) | Jazz Pharmaceuticals | |
| Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France (NCT02307812) | Eli Lilly and Company | |
| Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System Injuries (NCT03631056) | Humacyte, Inc. | |
| Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy (NCT03895528) | Eiger BioPharmaceuticals | |
| Inotuzumab Ozogamicin - PF-05208773 (NCT03127605) | Pfizer | |
| Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs) (NCT04334837) | Curium US LLC | |